Verastem Offers Long-Term Follow-Up Data From DYNAMO Study: Showed '47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma,' '88% of Patients had a Reduction in the Size of Target Lymph Nodes'